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Electric field enhanced molecular delivery for cancer research and treatment is a new technology that has demonstrated its effectiveness in clinical trials using bleomycin or cisplatin
(Heller, R., Gilbert, R., Jaroszeski, M. J. Clinical applications of electrocemotherapy.
Advanced Drug Delivery Reviews 35,119-129 (1999)), as chemotherapeutic agents. The
technology is being investigated in research applications for applicability as a method to
enhance gene expression in a target tumor. Success is predicated on an appropriate effective electric field mediated delivery protocol that triggers significant appropriate gene
expression duration and levels.
An electric field mediated delivery protocol includes a set of conditions associated with the
electric field, the electroporation signature, as well as parameters associated with the plasmid
and the electric field applicator. Manipulation of the electrical parameters within the electroporation signature generates different gene expression levels in liver hepatocellular carcinomas. Statistically significant gene expression levels were obtained that differed by an order of
magnitude when two different electric field strength and duration conditions were employed.
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Introduction
The successful performance of in vivo electroporation to achieve effective gene
expression while maintaining safe and efficient delivery requires optimal use of
the technology associated with electric field mediated gene delivery (1-6).
Traditionally, electroporation is performed using square-wave or exponentially
decaying waveforms (7). Recently, it has been demonstrated that different combinations of pulse profiles produce gene expression (8-9). Thus it appears that
an optimal use of electroporation for gene delivery as it applies to cancer
research and treatment requires initial investigation, characterization and then
selection of appropriate electroporation parameters.
An electric field mediated delivery protocol for research or treatment applications is based on a set of parameters that reflect the tissue target, the desired gene
expression level and duration, and the collection of electroporation conditions. It
is important to match the electroporation parameters to the target tissue as well
as the goal of the specific application. For example, when delivering plasmid
DNA to muscle, millisecond duration pulses of relatively low electric field
strengths yield the highest expression levels (10-11). In contrast, when using a
gene transfer approach to treat B16 murine melanoma tumors complete long lasting regressions can be obtained by delivering the plasmid using microsecond
duration high field strength pulses (12). It should also be noted that within a par-
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ticular tissue, different expression patterns could be obtained
by using different pulsing conditions (13).
The collection of electroporation conditions used for a specific expression event can be identified as an electroporation
signature. This designation is convenient since it separately
groups the electroporation conditions from the plasmid and
tissue parameters that must also be included in a successful
electric field mediated delivery protocol. Electroporation
signatures can be systematically altered to trigger high or
low level expression for a short or long duration, which
would allow manipulation of the expression patterns based
on the tissue application. This paper demonstrates the
impact of various electroporation signatures on a specific
tumor model, N1S1 hepatocellular carcinoma.
Materials and Methods
Hepatocellular Carcinoma Cell Line

Gilbert et al.
sutured close and skin is closed with surgical staples). Tumors
were allowed to grow for approximately 8 days, which resulted in tumor volumes that were about 100 mm3. These volumes
were calculated using the formula , V = [(a)(b)(c)(pi)]/6 , where
a, b and c represent three mutually orthogonal tumor dimensions as measured by a digital Vernier caliper.
Electrical Treatment
Electric pulses for this study were administered using an electroporation power supply and switch (PA 4000; Cytopulse
Sciences, Columbia, MD). Pulses were applied using a custom made array of electrodes consisting of seven 28 gauge
needles arranged in three parallel rows. The needles protruded from the end of the applicator’s plastic handle 5 mm. The
applicator was positioned so that the needles were located into
and around the tumors. The electroporation signatures used to
facilitate plasmid delivery to the tumor cells in this investigation are described in Figure 3 and summarized in Table I.

N1S1 rat hepatocellular carcinoma cells (ATCC CRL-1604;
American Type Culture Collection, Rockville, MD) were
grown in Swimms S-77 medium supplemented with 4mM Lglutamine, 0.01% Pluronic F68, 9% fetal bovine serum, and
90 µg/ml gentamicin. Cells were grown in standard tissue
culture flasks in an atmosphere that contained 5% CO2. Cell
viability was greater than 95% based on the trypan blue
exclusion dye method.

Tumor Treatment

Animals and Anesthesia
Male Sprague Dawley rats (Harlan Sprague Dawley, Inc.,
Indianapolis, IN) 7-8 weeks old (250 g) were used for this
study. Animals were housed and cared for according to NIH
guidelines. All methods used in this investigation were
approved by the University of South Florida Institutional
Animal Care and Use Committee (IACUC). Procedures were
conducted with animals that were under general anesthesia
using 3% isoflurane (Mallinckrodt Veterinary, Mundelein,
IL) in oxygen administered using a calibrated vaporizer.

The needle array applicator was immediately inserted into the
tumor following DNA injection. The needles of the array were
inserted into the entire tumor so that its volume was delineated
by the needle array. Electric pulses were then applied to the
tumor tissue for tumors that were scheduled to receive pulses.
The electric field strength, number of pulses and pulse duration
were experimental variables. The applicator was immediately
removed from the tumors after treatment and the animals were
immediately closed using surgical staples. For sham treatments, the applicator was inserted into the tumor in a manner
identical to those tumors that received pulses.

Tumor Induction

Luciferase Expression Assay

After rat is completely anesthetized, the right median lobes of
male Sprague Dawley rats were surgically exposed. This was
achieved by making a transverse incision starting from the mid
sagittal position, approximately 1 cm caudal to the xiphoid
process, extending 3 to 4 cm toward the dorsal surface of the
rat. The median lobe (both halves) of the liver was exposed by
drawing it out of the incision taking great care not to cause any
tissue damage. Then, each lobe was given a subcapsular injection of 1.5x106 viable N1S1 cells suspended in 0.05 ml of
saline. Following injection of the tumor cells, the liver is
placed back into the abdomen and the rat is closed (muscle is

Animals were humanely euthanized 48 hours after treatment.
Tumors were rapidly frozen using dry ice. Each frozen
tumor was weighed, homogenized and extracts were analyzed for luciferase activity (15).

Tumors in each animal were surgically exposed. Each tumor
scheduled for DNA delivery received an amount, 2 micrograms/microliter, pCMVLuc+ plasmid (14) solution based on
50% of the measured tumor volume. Tumors that were not
scheduled for DNA delivery were given an injection of saline
equal to 50% of the tumor volume as a sham DNA injection.

Results
A successful application of electric field mediated molecular delivery enhancement technology depends on many
parameters associated with the molecule, the target tissue,
and the electroporation signature. The use of this technolo-
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gy as a cancer research and treatment tool requires that an
electric field enhancement protocol signature suitable to
that treatment be established. This signature protocol will
contain all of the operational parameters required.
Characteristics such as pulse amplitude, length, pulse application frequency (duty cycle) pulse shape and applicator
design must be defined. This study explored reporter gene
expression in a liver tumor model with applicator design,
pulse shape and plasmid construction held constant.
Figure 1 presents the ensemble of observations for this investigation with respect to electric field enhanced delivery
response. The figure shows the luciferace expression levels in
relative light units per milligram of tumor (RLU) for 221 electroporation signature expression experiments. The graphic
not only indicates the sensitivity of the detected expression as
a function of electric field delivery enhancement experiments
but to replicate experiments as well. The figure summarizes
all of the experiments conducted including the replicate sets.
The index values on the horizontal axis only indicate that an
experiment has been performed. These index values are not
associated with the experimental conditions. Thus, Figure 1
illustrates for this study the range and value of luciferace
expression levels from different liver tumors in rats treated on
different days with various procedures.
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background RLU levels. The standard deviation for this data
set is 7151 RLU’s. Establishing a 3-sigma confidence level
indicates that only one of the control electroporation signature experiments produced a luciferace response outside this
3-sigma confidence limit. Although the electroporation signature expression results summarized in Figure 1 are presented with no specific overall sequential order in mind, the
control experiment sets were arranged to frame the other
experiments presented in the figure and are highlighted in
gray. Therefore, other experiments shown in Figure 1 with
similar low RLU/milligram of tumor responses represent
results that have a 99.99% probability of being random
responses triggered by an intended but in fact non-delivery
enhancing electroporation signature.

Figure 2: Control Electroporation Signature Response. Figure presents the
luciferace expression level data for all tumors treated with pCMVLuc+ plasmid but no application of electric field. The expression response level in control replicate experiment number 24 was outside the 3-sigma confidence limit.

Figure 1: Electric Field Enhanced Delivery Expression Results. Figure provides luciferace expression level data for all experiments performed in this
investigation. The Experiment Index number on the horizontal axis does not
indicate experimental conditions.

Figure 2 isolates all of the luciferace expression data for all
of the control electroporation experiments in Figure 1. A
control response is defined as luciferace expression that
results from an experiment that was not intended to demonstrate enhanced molecular delivery. For this investigation,
expression levels observed from tumors injected with plasmid but not exposed to an electric field represent control
responses. Visual examination of the expression levels presented and statistical analysis of this data set supports the
premise that the figure presents a random distribution of

The electroporation signatures presented in Table I represent
all of the signatures employed during the course of this
investigation. Although not stated, electroporation signature
0 exists. This is simply an electroporation procedure that
includes an injection of plasmid, placement of applicator
needles but no application of a voltage to the electrodes.
Figure 2 presents the expression data from tumors that were
subject to electroporation signature 0.
As suggested earlier, defining a successful electric field
delivery enhancement protocol requires an electroporation
signature and additional information about the intended molecule and the target tissue. Table I only reports the electroporation signature portion of the complete electric field
delivery enhancement protocol. Since the focus of this
investigation was the impact of the electroporation signature
on expression results, the plasmid, tumor and animal model
were held constant. The plasmid concentration was set at 2
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1
2
3
4
5
6
7
8
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Electroporation Signature
Description
7[(2x500V/cm, 100µs, 1s)]
7[2x750V/cm, 100µs, 1s]
7[2x1000V/cm, 100µs, 1s]
7[2x1500V/cm, 100µs, 1s]
7[(2x2000V/cm, 10µs, 1s)]
7[(2x2000V/cm, 25µs, 1s)]
7[(2x2000V/cm, 50µs, 1s)]
7[(2x2000V/cm, 100µs, 1s)]
7[(2x2000V/cm, 200µs, 1s)]
7[(2x2000V/cm, 500µs, 1s)]
7[(2x2000V/cm, 1µs, 1s)]
7[(1x2000V/cm, 100µs, 1s)]
7[(3x2000V/cm, 100µs, 1s)]
7[(4x2000V/cm, 100µs, 1s)]
7[(5x2000V/cm, 100µs, 1s)]
7[2x1500V/cm, 50µs, 1s]
7[(2x1500V/cm, 100µs, 1s)]
7[(2x1500V/cm, 100µs, 1s)]
7[(2x500V/cm, 100µs, 1s) 0.125s
+(5x30V/cm, 10ms, 1s)]
7[(2x500V/cm, 100µs, 1s) 0.125s
+(5x60V/cm, 10ms, 1s)]
7[(2x500V/cm, 100µs, 1s) 0.125s
+(5x100V/cm, 10ms, 1s)]
7[(2x500V/cm, 100µs, 1s) 0.125s
+(5x200V/cm, 10ms, 1s)]
7[(2x750V/cm, 100µs, 1s) 0.125s
+(5x30V/cm, 10ms, 1s)]
7[(2x750V/cm, 100µs, 1s) 0.125s
+(5x60V/cm, 100ms, 1s)]
7[(2x750V/cm, 100µs, 1s) 0.125s
+(5x100V/cm, 10ms, 1s)]

27
28
29
30
31
33
34
35
36
37
38
39
40
90
91

7[(2x750V/cm, 100µs, 1s) 0.125s
7[(2x750V/cm, 100µs, 1s) 0.125s
7[(2x1000V/cm, 100µs, 1s) 0.125s
7[(2x1000V/cm, 100µs, 1s) 0.125s
7[(2x1000V/cm, 100µs, 1s) 0.125s
7[(2x1500V/cm, 100µs, 1s) 0.125s
7[(2x1500V/cm, 100µs, 1s) 0.125s
7[(2x1500V/cm, 100µs, 1s) 0.125s
7[(2x1500V/cm, 100µs, 1s) 0.125s
7[(2x1500V/cm, 100µs, 1s) 0.125s
7[(2x1500V/cm, 50µs, 1s) 0.125
7[(2x1500V/cm, 50µs, 1s) 0.125
7[(2x1500V/cm, 50µs, 1s) 0.125
7[(2x1500V/cm, 100µs, 1s) 0.125
7[(2x1500V/cm, 100µs, 1s) 0.125

#

#
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
66

+(5x200V/cm, 10ms, 1s)]
67
+(5x60V/cm, 20ms, 1s)]
68
+(5x30V/cm, 10ms, 1s)]
69
+(5x60V/cm, 10ms, 1s)]
70
+(5x200V/cm, 10ms, 1s)]
72
+(5x15V/cm, 10ms, 1s)]
74
+(5x30V/cm, 10ms, 1s)]
76
+(5x60V/cm, 10ms, 1s)]
77
+(5x200V/cm, 10ms, 1s)]
78
+(10x30V/cm, 20ms, 1s)]
+(5x30V/cm, 10ms, 1s)]
92
+(5x60V/cm, 10ms, 1s)]
93
+(5x200V/cm, 10ms, 1s)]
+(5x30V/cm, 10ms, 1s)]
+(5x30V/cm, 10ms, 1s) 1-1ms pulse

micrograms per microliter except for electroporation signature number 18. In this case, the plasmid concentration was
1 microgram per microliter and an expression level value
was obtained for three replicate experiments. The average
expression for this 4-experiment data set was 99,254
RLU/milligram of tumor with a sigma value of 20,751
RLU’s. Thus, in this investigation the electric field
enhanced protocol that included electroporation signature 18
produced a statistically significant luceriferase expression
level with a RLU/milligram response value that was the
result of the tumor uptake of the plasmid and random experimental effects as characterized in Figure 2.
Figure 3 provides clarification of the succinct signature information summarized in Table I. This two-part figure presents
an example signature and a definition of the elements in that
electroporation signature. Part (a) of Figure 3 shows a drawn

Electroporation Signature
Description
7[(2x1500V/cm, 25µs, 1s) 0.125s
+(5x60V/cm, 20ms, 1s)]
7[(2x1500V/cm, 25µs, 1s) 0.125s
+(5x200V/cm, 20ms, 1s)]
7[(2x2000V/cm, 100µs, 1s) 0.125s
+(5x30V/cm, 10ms, 1s)]
7[(2x2000V/cm, 100µs, 1s) 0.125s
+(5x60V/cm, 10ms, 1s)]
7[(2x2000V/cm, 100µs, 1s) 0.125s
+(5x200V/cm, 10ms, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(5x30V/cm, 10ms, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(5x60V/cm, 10ms, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(5x100V/cm, 10ms, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(5x200V/cm, 10ms, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(5x100V/cm, 100µs, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(5x200V/cm, 100µs, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(5x400V/cm, 100µs, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(15x200V/cm, 100µs, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(5x60V/cm, 100µs, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(1x60V/cm, 100µs, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(1x60V/cm, 500µs, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(1x60V/cm, 1ms, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(1x60V/cm, 10ms, 1s)]
7[(2x2000V/cm, 25µs, 1s) 0.125s
+(1x60V/cm, 20ms, 1s)]
7[(1x2000V/cm, 100µs, 1s) 0.125s
+(5x60V/cm, 100µs, 1s)]
7[(1x2000V/cm, 100µs, 1s) 0.125s
+(5x60V/cm, 500µs, 1s)]
7[(1x2000V/cm, 100µs, 1s) 0.125s
+(5x60V/cm, 1ms, 1s)]
7[(1x2000V/cm, 100µs, 1s) 0.125s
+(5x60V/cm, 10ms, 1s)]
7[(1x2000V/cm, 100µs, 1s) 0.125s
+(5x60V/cm, 20ms, 1s)]
7[(5x30V/cm, 10ms, 1s) 0.125s
+(2x750V/cm, 100µs, 1s) 0.125s
+ (5x30V/cm, 10ms, 1s)]
7[(5x60V/cm, 10ms, 1s) 0.125s
+(2x2000V/cm, 25µs, 1s)]
7[(5x60V/cm, 10ms, 1s) 0.125s
+(2x2000V/cm, 10µs, 1s)]
7[(5x60V/cm, 10ms, 1s) 0.125s
+(2x2000V/cm, 100µs, 1s)]
7[(5x15V/cm, 10ms, 1s)]
71 7[(5x30V/cm, 10ms, 1s)]
7[(5x60V/cm, 10ms, 1s)]
73 7[(5x100V/cm, 10ms, 1s)]
7[(10x30V/cm, 20ms, 1s)]
9
Signature not assigned
7[(5x200V/cm, 10ms, 1s)]
32
Signature not assigned
7[5x60V/cm, 20ms, 1s)]
65
Signature not assigned
7[(5x200V/cm, 20ms, 1s)]
75
Signature not assigned
79
through 91 not assigned
7[(2x750V/cm, 100µs, 1s) 0.125s
+(5x30V/cm, 10ms, 1s)]
7[(2x750V/cm, 100µs, 1s) 0.125s
+(5x30V/cm, 10ms, 1s)]
1-1µs pulse

to scale field strength waveform that results when electroporation signature 36 is applied to a tumor. Note that the time
axis is not to scale but the duration of the pulse widths is indicated. Three of the five 10 millisecond pulses prescribed in
signature 36 are not shown because of graphic constraints on
the figure. Section (b) of the same figure presents the specific electroporation parameters associated with signature 36.
Thus, for this investigation, electroporation signature 36 consists of two 1500 v/cm pulses with a duration of 100
microseconds separated by a one second delay and then five
200 v/cm pulses with a pulse duration of 10 milliseconds and
a delay of 1 second between each pulse. This entire pulse pattern was applied to each target tumor seven times.
Electroporation signature 36 was also employed in this investigation 4 different times with the mean expression level for
that group being 158,091 RLU’s /milligram of tumor with a
standard deviation of 104,359 RLU’s.
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associated with electroporation signature
numbers between 0 and 20 indicated the
degree of repeated use of these signatures in
different tumors. The complete blur of symbols at the 0, 1, 2 and 3 marks on the horizontal axis indicate the tight gathering of
responses for those four electroporation signatures. Expression level data for all electroporation signatures used in this investigation
are presented in Figure 4.

Figure 5 sharpens the information focus for
review of the results by presenting the replicate
response data from Figure 4 after culling the
non-expression responding electroporation
signatures. The 3-sigma value from the control group was taken as the cull criteria and
electroporation signature experiments that did
not involve replicate experiments were also
removed. Thus Figure 5 does not show
response symbols for electroporation signatures number 0 through number 3, numbers 20
Figure 3: Electroporation Signature Characterization and Description. This two-section figure through 22, and numbers 24 through 28
presents; (a) The waveform for electroporation signature number 36; (b) the placement and defibecause all of the luciferace expression levels
nition of electroporation parameters within an electroporation signature.
for those experiments were below 21,453
RLU’s /milligram of tumor. No entries are
provided for electroporation signatures numbers 28
through 33 because no replicate experiments were
conducted. No data is shown for signature 19 since it
used a different plasmid delivery solution. In this singular set of 4 experiments, 2 micrograms/microliter
of plasmid was used in hypertonic 25% sucrose. The
average luciferase expression for this four-element
data set was 83,681 RLU with a standard deviation of
30,016 RLU’sThe two-symbol entry for electroporation signature 23 reports an initial experiment and a
single repeat experiment. That replicate experiment
expression level response is indicated by the square
symbol.
The collection of symbols in Figure 5 shown for
electroporation signature number 4 indicate additional replicate measurements. Signature number 4
Figure 4: Expression Level Response. Figure provides luciferace expression level
was used in 18 separate experiments. It represents
data for all experiments performed in this investigation as a function of the electropothe most number of repeat experiments with 17
ration signature used in the experiment. Figure also includes replicate experiments.
The various symbols are used to indicate replicate experiments. The solid diamond is
replicate symbols shown superimposed on the graph
the first experiment while the solid square represents the first replicate. Different
with the solid diamond shape also representing the
shapes identify other repeated signature experiments.
first experiment of the set. In all cases, replicated
signature experiments were done on different
tumors from different animals and primarily on difThe replicate nature of this entire investigation is the focus
ferent
days.
Finally, Figure 5 does not report the replicate
of Figure 4 and Figure 5. Figure 4 illustrates all of the elecexperiments
for
signature 71 and72. The results of these
troporation signatures used in this study with replicate appliexperiments
are
illustrated
in Figure 6.
cations of specific electroporation signatures indicated by
different symbols. Thus, the large cluster of graphic symbols
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Figure 5: Replicate Electroporation Signature
Expression Response. Figure provides luciferace
expression level data for pCMVLuc+ plasmid delivery experiments that produced expression level data
significantly above the background expression level
value. Only repeated signature experiments are
shown. For example, signature 23 was used in two
experiments. The first is shown as a solid diamond,
the replicate is indicated as a solid square. Signature
34 was used in 5 experiments with the triangle representing the second replicate, the solid circle the
third replicate and the cross the last replicate or fifth
experiment of the set.

Figure 6: Electroporation Signature Influence of
Expression Response. Figure provides luciferace
expression level data for pCMVLuc+ plasmid delivery experiments that produced expression level data
significantly above the background expression level
value. The signature 8 presentation bar represents 9
experiments with a mean of 530,024 RLU’s and
standard deviation of 298,458 RLU’s. Signature 76
presentation bar represents 4 experiments with a
mean of 56,903 and a standard deviation of 29,061.

Electric fields can mediate the delivery of genes to target tissues, however the choice of an electric field mediated transfer protocol will have an impact on that mediation. One
strategy for enhancing plasmid delivery is to expose the target tumor with a uniform but short duration electric field that
will provide excess activation energy to temporarily
rearrange the cell membrane and permit the plasmid access
to the cell. A second option is to expose the tissue to a long
duration electric field that may allow the target membrane to
establish a fluidic-like semi-stable steady state condition. As
suggested from previous studies, different expression results
can be initiated by different electric field stimulation. For
the hepatocellular carcinoma model used in this study, the

reporter gene expression was influenced significantly by the
electroporation signature employed in the experiment.
Figure 6 summarizes the expression results for electroporation signature numbers 4, and 8 as well as for signatures 71,
72 and 76. Signatures 4 and 8 represent the short duration
high field experiments. The mean expression levels for these
two signatures are 530,024 RLU’s and 169,609 RLU’s
respectively. Their corresponding standard deviations are
298,458 RLU’s and 28,943 RLU’s, respectively. The
expression levels observed from these two experiment
groups are distinctively different with the 2,000 v/cm field
producing the highest expression. By contrast, the longer
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duration but considerably lower field strength situation as
represented by electroporation signatures 71, 72 and 76,
stimulated expression levels that are an order of magnitude
lower than the short duration, high field strength situation.
Although luciferase expression generated by signatures 71,
72 and 76 were markedly lower, they were also significantly
different from the control expression levels.
Discussion
Insight into the influence of an applied electric field and its
molecular delivery-enhancing characteristic on liver tumors
may also be gleaned from the expression level results of
other electroporation signatures used in this investigation.
All of the luciferase expression data presented in Figure 5 is
significantly different from the control signature expression
levels. Many of the individual electroporation signature
results reported in the figure include a large number of replicate experiments. Any randomization of luciferase response
that might be expected from an experiment that had a random selection of animal, tumor size and day of treatment
was not observed throughout the data set. Specific reasons
for such variations in the response data include the effects of
large tumor necrosis, plasmid leakage during injection, and
variations in tumor growth rates.
A visual as well as statistical examination of the multiple entry
expression data sets in Figure 5 indicates that the mean expression and variance in expression values for electroporation signatures 4, 5 and 6 is significantly lower and tighter, respectively, than the corresponding statistical parameters for electroporation signature number 8. At least 9 data points were obtained
in each of these experimental groupings. An examination of
Table I indicates that pulse duration, 100 microseconds, distinguishes electroporation signature 8 from signatures 5 and 6
while its field strength is 500 volts/cm higher than prescribed
for signature number 4. Thus, the energy needed to facilitate
plasmid passage through the cell membrane is not necessarily
quantized but is influenced by the surface topography and the
local environment of individual tumors. This cell individuality will dictate different electroporation energy requirements for
different cells within the tumor.
The potential energy available to a tumor cell is proportional
to the charge build up on the cell and that charge is directly
proportional to the cell’s exposure to the electric field’s
strength and duration. Specific cells in a tumor can be classified as capacitors with capacitance values that depend on their
size and membrane properties. Thus, cells within a tumor are
an assembly of “in vivo” capacitors with a range of capacitance values. When the electric field is applied for a period of
time, the applied voltage and the charge transfer associated
with these capacitors represents an energy transfer to the
tumor cells. If an excess of potential energy is available, all
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the cells in this assembly will be electroporated, if not, only
cells with an electroporation energy requirement that matches
the available potential energy will be electroporated.
When excess potential energy was provided to the liver
tumors in this study, as is the case for signatures 8 and 10
through 16, the range of expression levels is wide. Tumors
with a band of higher localized energy requirements for successful plasmid transport through the cell membrane may
still have the needed energy for plasmid delivery. By contrast, when the available energy is less but adequate, as in the
case of signature 4, tumor cells with higher localized energy
requirements do not have plasmid transport through the cell
membranes and the range of possible expression levels is
diminished. Energy levels less than adequate, as the case of
signatures 1, 2 and 3, did not result in detectable expression
levels in this heptaocellular carcinoma tissue model.
For this study, adequate energy is classified as the energy
associated with a 2 pulse 100 microsecond 1500 v/cm electric field or the energy from a 2000 v/cm electric field as
generated by two less than 50 microsecond duration pulses.
Electroporation signatures 4, 5 and 6 fall within this category. This heuristic characterization of an adequate amount of
available energy emanates from several expression level
observations from the data set. First, the luciferase expression in tumors exposed to electroporation signatures 1
through 3 was not significant. These signatures involve 100
microsecond field duration but field strengths less than 1500
v/cm. Second, signatures 4 through 6 have a tight distribution of expression level results. Third, the mean expression
value and its variation for experiments that used electroporation signature number18 is one of the lowest and tightest
within the entire investigation.
Electroporation signature 18 has electrical parameter values
that are identical to electroporation signature number 4 however; the range of expression results from signature 18 is much
tighter than those recorded for electroporation signature 4.
Actually, these two identical signatures are part of two different electric field delivery enhancement protocols. Signature
number 18 is used with a 1 microgram/microliter plasmid concentration while electroporation signature 4 uses a 2 microgram/microliter plasmid concentration. Thus, the luciferase
expression levels observed with electroporation signature 18
were not limited by the potential energy available for electroporation of the target tumor cells but mass transport limited by
the amount of plasmid available at the tumor cells.
Careful examination of Figure 5 suggests that adequate
potential energy may also be obtained by manipulating the
number of pulses applied to the tumor. The mean expression
level associated with the excess energy available because of
the 2000 v/cm 100 microsecond pulse in electroporation sig-
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nature 13 is the same order of magnitude as the mean expression values obtained from experiments that used the various
adequate energy options associated with electrical signatures
4, 5 and 6. This energy mollification of signature 13 was
accomplished by the administration of a single 100
microsecond 2000 v/cm pulse instead of the double 100
microsecond 2000 v/cm pulses prescribed in experiments
using electroporation signature 8, 10 and 11.
The luciferase expression levels and distributions associated
with electroporation signatures 76 suggest a different electric
field effect on the target liver tumor cells. Traditionally, electroporation has been associated with a threshold field
strength concept. In fact, the tumor experiments that used
electroporation signatures 1, 2, and 3 in this study add
strength to that conventional perspective. However, electroporation signature 76 does not meet this field strength threshold expectation even though significant expression levels
were detected in 3 of the 4 experiments conducted. Thus,
there was enough energy presented to the tumor to allow the
cell membranes to develop a semi-fluidized state that permitted plasmid transport in such a manner that a steady state
concentration of plasmid was established on either side of the
membrane before the termination of the electric field.
The experiments that involved electroporation signatures 34,
35, and 36 represent a set of plasmid transport experiments
that use electroporation signature 4 energy field condition,
1500 v/cm for 100 milliseconds, before the application of the
non-electroporation field conditions similar to signature 76.
In fact, the second part of electroporation signature 36, five
10-millisecond duration 200 v/cm pulses, is identical to electroporation signature 76. The results of these experiments
are similar to those obtained in electroporation experiments
4,5 and 6. The mean expression and its variance for signatures 34, 35 and 36 are similar to those for signatures 4, 5 and
6 but different than the corresponding parameters for signature 76. This suggests the termination of the electroporation
event returned the membrane to its normal state and the mass
transport condition established by signature 76 is different
than the electroporation condition established by signatures
with higher field strength components.
An extended pulse duration that did allow a concentration
steady state condition may have occurred with electroporation signature number 12. With the exception of one experiment which might be discounted since it has the singularly
highest recorded expression level presented in Figure 1, the
spread of reporter gene expression levels triggered by signature 12 are lower than the other excess energy signatures used
in this investigation. This suggests that the millisecond pulse
duration in signature 12 also allowed plasmid to move in the
reverse direction across the cell membrane. Such plasmid
reverse direction transport was not significant in the other
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excess energy signatures because the pulse duration, 100
microseconds, was not adequate to build up a sufficient concentration gradient of reporter gene inside the tumor cells.
In summary, a more detailed qualitative picture of electric
field interactions with liver tumors has been developed.
Expression levels in hepatocellular carcinoma tumors were
manipulated after fixing the plasmid concentration and the
electric field applicator geometry by systematically varying
the parameters within the electroporation signature. Any
response randomization effect that might be expected from an
experiment that had a random selection of animal, tumor size
and day of treatment was not observed throughout the data
set. In addition, electroporation conditions that provide adequate or excess potential energy to facilitate plasmid delivery
via electroporation were determined. Finally, delivery
enhancement electroporation signatures that favored steady
state plasmid mass transport conditions for liver tumors were
identified. This array of options for plasmid DNA delivery to
liver tumors will now be explored with respect to the gene
expression requirements for potential liver tumor treatments
to optimize the effect of such treatment protocols.
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